Increasing radiation therapy and lower survival for human papillomavirus-related oropharynx cancer associated with a shift to community cancer center care

被引:1
|
作者
Trakimas, Danielle R. [1 ]
Mydlarz, Wojtek [1 ]
Mady, Leila J. [1 ]
Koch, Wayne [1 ]
Quon, Harry [1 ,2 ]
London, Nyall R., Jr. [1 ]
Fakhry, Carole [1 ,3 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Radiat Oncol, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD USA
来源
基金
美国国家卫生研究院;
关键词
HIGH-VOLUME FACILITIES; SHORT-TERM OUTCOMES; HOSPITAL VOLUME; HEAD; SURGERY; COST; TRENDS; PREVALENCE; CARCINOMA; IMRT;
D O I
10.1093/jnci/djad238
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies have shown lower overall survival for patients with head and neck cancer treated at low-volume or community cancer centers. As the incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma steadily rises in the United States, we hypothesized that a greater proportion of patients with HPV-related oropharyngeal squamous cell carcinoma is being treated at community cancer centers, with a shift toward primary nonsurgical treatment.Methods: This cohort study included patients from the US National Cancer Database who received a diagnosis of HPV-related oropharyngeal squamous cell carcinoma from 2010 to 2019 and underwent treatment at a community cancer center or academic cancer center. The proportion of patients with HPV-related oropharyngeal squamous cell carcinoma treated at community cancer centers and receiving primary nonsurgical treatment was analyzed over time. Four-year overall survival was compared between community cancer centers and academic cancer centers.Results: The majority (67.4%) of 20 298 patients were treated at an academic cancer center, yet the proportion of patients treated at community cancer centers increased by 10% from 2010 to 2019 (P < .01 for trend). The proportion of patients undergoing primary nonsurgical treatment increased from 62.1% to 73.7% from 2010 to 2019 (P < .01 for trend), and patients were statistically significantly more likely to undergo nonsurgical treatment at community cancer centers than at academic cancer centers (adjusted odds ratio = 1.20, 95% confidence interval = 1.18 to 1.22). Treatment at community cancer centers was associated with worse survival overall (adjusted hazard ratio = 1.19, 95% confidence interval = 1.09 to 1.31), specifically for patients receiving primary nonsurgical treatment (adjusted hazard ratio = 1.22, 95% confidence interval = 1.11 to 1.34).Conclusions: Treatment of HPV-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall survival at these centers compared with academic cancer centers. Concentration of care for HPV-related oropharyngeal squamous cell carcinoma at academic cancer centers and dedicated head and neck cancer centers may increase access to all available treatment modalities and improve survival.
引用
收藏
页码:1051 / 1062
页数:12
相关论文
共 50 条
  • [31] HYHOPE: A Phase I Study of De-Intensified Hypofractionated Radiation Therapy for Human Papillomavirus Associated Oropharynx Cancer
    Moon, D. H.
    Avkshtol, V.
    Hughes, R.
    Sher, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S122 - S122
  • [32] Human papillomavirus genotype and oropharynx cancer survival in the United States of America
    Goodman, Marc T.
    Saraiya, Mona
    Thompson, Trevor D.
    Steinau, Martin
    Hernandez, Brenda Y.
    Lynch, Charles F.
    Lyu, Christopher W.
    Wilkinson, Edward J.
    Tucker, Thomas
    Copeland, Glenn
    Peters, Edward S.
    Altekruse, Sean
    Unger, Elizabeth R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2759 - 2767
  • [33] Variations in Human Papillomavirus Vaccination and Human Papillomavirus-Related Cancer Rates in Texas, United States
    Adekanmbi, Victor
    Sokale, Itunu
    Guo, Fangjian
    Ngo, Jessica
    Hoang, Thao N.
    Hsu, Christine D.
    Oluyomi, Abiodun
    Berenson, Abbey B.
    JOURNAL OF WOMENS HEALTH, 2024, 33 (09) : A7 - A8
  • [34] Two Cases of Human Papillomavirus-Related Oropharyngeal Cancer After the Treatment of Cervical Cancer
    Yamazaki, Tomoko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [35] The role of regulatory T cells in pathogenesis and therapy of human papillomavirus-related diseases, especially in cancer
    Ao, Chunping
    Zeng, Kang
    INFECTION GENETICS AND EVOLUTION, 2018, 65 : 406 - 413
  • [36] Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer
    Hung, Tony K. W.
    Ho, Alan L.
    Pfister, David G.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (06) : 952 - 961
  • [37] Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer
    Faraji, Farhoud
    Zaidi, Munfarid
    Fakhry, Carole
    Gaykalova, Daria A.
    MICROBES AND INFECTION, 2017, 19 (9-10) : 464 - 475
  • [38] Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States
    Eytan, Danielle F.
    Blackford, Amanda L.
    Eisele, David W.
    Fakhry, Carole
    CANCER, 2019, 125 (02) : 249 - 260
  • [39] Patient-reported outcomes in human papillomavirus-related oropharyngeal cancer
    Fitzgerald, Conall W. R.
    Long, Sallie M.
    McLean, Andrew T.
    Cracchiolo, Jennifer R.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (06) : 967 - 976
  • [40] Commentary: Clinical Nodal Staging of Human Papillomavirus-Related Oropharyngeal Cancer
    Chepeha, Douglass
    Eisbruch, Avraham
    CANCER JOURNAL, 2010, 16 (03): : 283 - 283